



REVIEW ARTICLE

OVERCOMING CHEMORESISTANCE IN CERVICAL CANCER: PHARMACOLOGICAL HURDLES AND NEW FRONTIERS

Christian C. Ezeala¹

Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.

Article Info:



Article History:

Received: 6 April 2025
Reviewed: 12 May 2025
Accepted: 19 June 2025
Published: 15 July 2025

Cite this article:

Ezeala CC. Overcoming chemoresistance in cervical cancer: Pharmacological hurdles and new frontiers. Universal journal of pharmaceutical research 2025; 10(3): 91-96.
<http://doi.org/10.22270/ujpr.v10i3.1368>

*Address for Correspondence:

Christian C. Ezeala, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe. Tel: +234 803 736 9912;
E-mail: ezeala_ca@yahoo.com

Abstract

Chemoresistance continues to be a significant obstacle to successful treatment of cervical cancer, especially in advanced and recurrent situations. Even with the effectiveness of cisplatin-based chemoradiotherapy as a standard option, numerous patients develop resistance that greatly diminishes therapeutic effectiveness and leads to unfavorable clinical results. The fundamental mechanisms of resistance are complex and include cellular, molecular, and microenvironmental alterations that enable tumor cells to endure cytotoxic attacks. Important pharmacological mechanisms involve the overexpression of efflux transporters like P-glycoprotein, improved DNA repair abilities, avoidance of apoptosis, and resistance induced by hypoxia within the tumor microenvironment. These adaptive responses allow cervical cancer cells to counteract the impacts of chemotherapy drugs. Tackling these mechanisms necessitates a comprehensive strategy that merges traditional chemotherapy with new approaches like targeted treatments, immune therapies, and advancements in drug delivery. New approaches like PARP inhibitors, immune checkpoint blockade, and nanoparticle-based drug delivery appear effective in reviving drug sensitivity and enhancing results. Furthermore, pharmacogenomic profiling provides a tailored method for choosing treatments that considers unique genetic differences.

Keywords: Cervical cancer, chemoresistance, drug delivery, pharmacogenomics, targeted therapy.

INTRODUCTION

Cervical cancer is a significant worldwide health issue, being the fourth most prevalent cancer in women across the globe^{1,2}. It is most common in low- and middle-income nations, where routine screening and HPV vaccination access is restricted. The condition is mainly triggered by ongoing infections with high-risk strains of human papillomavirus (HPV), particularly HPV-16 and HPV-18. Timely identification via cytological screening and preventive vaccination has considerably lowered the incidence of cervical cancer in affluent areas; nonetheless, numerous women continue to exhibit advanced stage illness upon diagnosis, requiring systemic treatment strategies³⁻⁶. The conventional approach for locally advanced cervical cancer is cisplatin-based chemoradiotherapy, demonstrated to enhance survival rates in comparison to radiotherapy alone. Nonetheless, although there is initial responsiveness to chemotherapy, numerous patients face disease recurrence or advancement. Recurrent and metastatic cervical cancer continues to be challenging to manage, offering few treatment alternatives and a bleak outlook. The main cause of

treatment failure in these cases is the emergence of resistance to chemotherapy drugs, commonly known as chemoresistance^{7,8}.

Chemoresistance can be either intrinsic occurring before treatment or acquired, emerging due to ongoing drug exposure. Multiple molecular and cellular processes lead to this resistance, encompassing changes in drug transport and metabolism, increased DNA repair ability, avoidance of apoptosis, and modifications in the tumor microenvironment like hypoxia. These processes allow tumor cells to endure and adjust when confronted with cytotoxic therapy, ultimately reducing the efficacy of standard chemotherapy^{9,10}. From a pharmacological viewpoint, tackling chemoresistance necessitates a comprehensive understanding of these resistance mechanisms and their interactions with current treatment approaches. The increased expression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein, can efficiently pump drugs like cisplatin and paclitaxel out of cancer cells, leading to lower intracellular levels and diminishing cytotoxic impacts. Likewise, excessive activation of DNA repair mechanisms can counteract

DNA damage caused by chemotherapy, enabling cancer cells to persist in their growth¹⁰.

The aim of this review is to critically examine the pharmacological mechanisms underlying chemoresistance in cervical cancer, explore current and emerging therapeutic strategies to overcome these challenges, and highlight future directions for research and clinical practice aimed at improving treatment outcomes in resistant and recurrent cases.

METHODS

This review employed a narrative approach to synthesize and critically evaluate current literature on chemoresistance in cervical cancer and related pharmacological interventions. A comprehensive search was conducted across multiple electronic databases including PubMed, Scopus, Web of Science, and Google Scholar to identify relevant peer-reviewed articles published between 2000 and 2024. Search terms included combinations of keywords such as “cervical cancer”, “chemoresistance”, “pharmacological strategies”, “drug resistance mechanisms”, “targeted therapy”, “immunotherapy”, and “nanoparticle drug delivery”. Studies were selected based on their relevance to the topic, scientific rigor, and contribution to understanding the biological mechanisms of chemoresistance or the development of novel pharmacologic interventions. Both preclinical (*in vitro* and *in vivo*) and clinical studies were included to ensure a broad and integrated perspective. Reviews, original research articles, and high-impact clinical trial reports were prioritized to provide a comprehensive overview of current knowledge and future prospects. The synthesis of findings was structured around key thematic areas including mechanisms of resistance, pharmacological strategies to overcome resistance, clinical and translational challenges, and future directions. As a narrative review, this report does not include a systematic assessment of study quality or risk of bias but instead offers a scholarly and critical integration of the available evidence to guide future research and clinical innovation.

Mechanisms of chemoresistance in cervical cancer

The ineffectiveness of chemotherapy in cervical cancer, especially in cases of recurrence or metastasis, is frequently due to the emergence of chemoresistance. This resistance can be inherent from the beginning (intrinsic resistance) or developed after continuous exposure to chemotherapy drugs. Chemoresistance is a multifaceted phenomenon that entails a complex interaction of cellular processes, genetic changes, and adaptations to the microenvironment. A comprehensive grasp of these mechanisms is crucial for creating effective approaches to address treatment failure¹¹. A key mechanism of chemoresistance in cervical cancer is the increased expression of drug efflux transporters, especially from the ATP-binding cassette (ABC) superfamily. Among these, P-glycoprotein (P-gp), which is encoded by the MDR1 gene, has a key role. P-gp operates as an energy-requiring pump that actively removes chemotherapeutic drugs from cancer cells, which lowers their intracellular levels to sub-

therapeutic amounts. This process reduces the effectiveness of medications like cisplatin, paclitaxel, and doxorubicin, frequently employed in cervical cancer therapy. The overproduction of alternative efflux proteins such as MRP1 and BCRP has likewise been associated with comparable resistance patterns¹².

A notable factor in chemoresistance is the increased capacity of cancer cells to mend DNA damage. Chemotherapy agents, especially platinum compounds, produce their cytotoxic impacts by creating DNA adducts and causing strand breaks, which result in apoptosis. Cervical cancer cells can enhance DNA repair mechanisms like nucleotide excision repair (NER) and homologous recombination (HR), enabling effective repair of DNA damage caused by chemotherapy. Heightened expression of genes related to these pathways, such as ERCC1 and BRCA1/2, has been linked to diminished sensitivity to cisplatin. This improved repair ability allows cancer cells to endure and grow even in the face of ongoing chemotherapy damage¹³. Avoidance of apoptosis also significantly contributes to the emergence of chemoresistance. In numerous cervical tumors, apoptotic pathways are altered because of mutations or misregulation of essential regulatory proteins. The tumor suppressor p53, often inactivated in HPV-related cervical cancer by the viral oncoprotein E6, plays a crucial role in apoptosis triggered by DNA damage. The absence of functional p53 hinders the cell's capacity to undergo programmed cell death after chemotherapy. Moreover, the overproduction of anti-apoptotic proteins like Bcl-2, Bcl-xL, and survivin enhances the inhibition of apoptotic signaling and encourages cell survival during cytotoxic stress¹⁴.

The tumor microenvironment (TME) greatly affects chemoresistance as well. A significant characteristic of various solid tumors, such as cervical cancer, is hypoxia a state of reduced oxygen levels that changes tumor biology. Hypoxic tumors typically show diminished responsiveness to chemotherapy because of limited drug access and the activation of survival mechanisms. Additionally, the TME consists of different stromal cells, immune cells, and extracellular matrix elements that engage with cancer cells to facilitate tumor development and resistance strategies¹³. Recent findings also emphasize the importance of cancer stem cells (CSCs) in promoting chemoresistance. CSCs signify a subset of cancer cells that possess the ability to self-renew and show natural resistance to standard treatments. These cells are thought to endure the initial therapy and aid in tumor recurrence and spread. In cervical cancer, markers like CD133 and ALDH1 have been found in CSC-like populations that exhibit resistance to chemotherapy and radiotherapy. Focusing on these cells could be essential for attaining long-lasting treatment responses¹⁴.

Pharmacological strategies to overcome chemoresistance in cervical cancer

To tackle chemoresistance in cervical cancer, a comprehensive and adaptive pharmacological strategy is necessary, focusing on the molecular basis of resistance as well as the shortcomings of standard chemotherapeutic administration. With a deeper

understanding of resistance mechanisms, new strategies have developed that focus on particular pathways, improve drug delivery, and tailor treatment according to individual tumor characteristics. These drug developments are transforming the approach to cervical cancer treatment, especially for individuals with recurrent or treatment-resistant conditions¹⁵. A key approach includes the creation and application of combination treatments. Merging conventional chemotherapeutic drugs with agents that block resistance mechanisms can enhance the effectiveness of the treatment. For example, the simultaneous use of cisplatin alongside DNA repair inhibitors like PARP (poly ADP-ribose polymerase) inhibitors has demonstrated potential in early-stage studies. PARP inhibitors hinder the repair of DNA single-strand breaks, thus amplifying the cytotoxic impact of DNA-damaging agents such as cisplatin. Likewise, the combination of chemotherapeutic agents with inhibitors of efflux transporters like P-glycoprotein has been investigated to enhance intracellular drug retention. These synergistic combinations seek to overcome known resistance mechanisms and improve the elimination of tumor cells¹⁶.

An alternative hopeful approach is the use of targeted therapies that focus on particular molecular irregularities in cervical cancer cells. One example of this agent is bevacizumab, a monoclonal antibody that blocks vascular endothelial growth factor (VEGF). By focusing on angiogenesis a process frequently enhanced in chemoresistant tumors bevacizumab interrupts the tumor's blood flow and boosts the efficacy of simultaneous chemotherapy. Additional molecular targets being studied are the PI3K/AKT/mTOR and EGFR pathways, which are essential for cell growth and survival. Blocking these signaling pathways might make cancer cells more responsive to chemotherapy and aid in overcoming resistance¹⁷. Recently, immunotherapy has surfaced as an intriguing approach, especially for tumors exhibiting immune-evasive traits. Immune checkpoint inhibitors like pembrolizumab, aimed at the PD-1/PD-L1 pathway, have demonstrated promising outcomes in a specific group of cervical cancer patients exhibiting high PD-L1 levels. By revitalizing immune responses against tumors, these agents can indirectly improve the effectiveness of chemotherapy. Additionally, strategies that combine immunotherapy with chemotherapy or targeted therapy are currently undergoing active research, seeking to leverage possible synergistic effects and address resistance via immune modulation¹⁸.

To tackle the issues of drug distribution and bioavailability, delivery systems based on nanoparticles have attracted interest. These systems provide numerous benefits, such as increased drug solubility, extended circulation duration, and greater accumulation at the tumor location through the enhanced permeability and retention (EPR) effect. Nanocarriers can also be designed to evade drug efflux transporters and deliver their contents directly inside tumor cells. Liposomal doxorubicin formulations, polymeric nanoparticles containing cisplatin, and

ligand-targeted drug delivery systems are among the novel strategies under investigation in clinical and preclinical research. These technologies improve treatment effectiveness while minimizing overall toxicity^{19,20}. Simultaneously, the emergence of pharmacogenomics has opened up the opportunity to customize treatment according to a patient's genetic profile. Genetic differences can affect drug metabolism, transport, and response, influencing both effectiveness and toxicity. For instance, variations in genes like GSTP1 (associated with drug detoxification) or ERCC1 (related to DNA repair) could indicate resistance to cisplatin and inform alternative treatment options. Incorporating genomic and transcriptomic profiling into clinical choices could enable personalized therapy options, reducing ineffective treatments and enhancing patient outcomes²¹.

Challenges in overcoming chemoresistance in cervical cancer

Even with major progress in comprehending the biological mechanisms of chemoresistance and creating new therapeutic strategies, various obstacles still impede advancements in addressing treatment resistance in cervical cancer. These obstacles encompass biological intricacy, clinical implementation, healthcare systems, and socio-economic inequalities, which all hinder the effective conversion of research results into enhanced patient outcomes²². A primary challenge is the molecular and genetic diversity of cervical cancer. Tumors may show considerable variability in genetic mutations, epigenetic alterations, and the expression of proteins related to resistance, both within and between patients. This diversity results in varying reactions to treatment, complicating the creation of universal therapeutic approaches. Additionally, resistance frequently includes redundant or compensatory pathways, indicating that blocking one target might not be enough to overcome resistance. Tumors can swiftly adjust by employing different survival strategies, highlighting the necessity for multi-targeted or combination treatments that are thoughtfully created and tailored to individuals²³.

Restricted availability and accessibility of sophisticated diagnostic tools represent another significant obstacle, especially in low-resource environments where cervical cancer is most common. The effective execution of pharmacogenomics, biomarker-driven treatment, and molecular profiling relies on access to high-throughput sequencing technologies, tissue biobanks, and experienced staff. In various areas, these resources are limited or completely lacking, leading to postponed or inadequate treatment choices. Even when these tools are available, the incorporation of molecular data into standard clinical practice is still restricted, and the cost-effectiveness of extensive genomic testing in cervical cancer has not been definitively proven. The clinical application of innovative therapies encounters significant challenges as well. Although targeted agents, immunotherapies, and nanoparticle-based systems have displayed potential in preclinical and early clinical trials, numerous methods have not yet shown substantial survival advantages in extensive,

randomized studies. Additionally, the toxicity profiles, ideal dosing schedules, and long-term safety of these newer drugs continue to be areas of concern. For instance, merging immunotherapy with chemotherapy could heighten immune-related side effects, whereas innovative drug delivery systems might trigger unexpected reactions or bio-distribution challenges in humans. These uncertainties further hinder regulatory approval and broad clinical adoption²⁵.

Economic and logistical challenges exacerbate these issues. Elevated expenses and restricted reimbursements for innovative treatments like checkpoint inhibitors and targeted therapies present significant obstacles to their utilization, especially in low- and middle-income nations that carry the heaviest incidence of cervical cancer. Even when medications are accessible, sustaining supply chains, guaranteeing cold storage, and handling intricate administration protocols can be challenging in health systems with limited resources. These structural constraints worsen disparities in healthcare access and lead to worse results for underserved groups²⁶. Factors related to patients also have an impact. Late presentation, inadequate compliance with treatment guidelines, and the stigma linked to cervical cancer can hinder treatment effectiveness and follow-up. Numerous patients arrive with progressed illness because of insufficient screening or health education, reducing the opportunity for effective treatment. Moreover, psychosocial obstacles like fear, cultural beliefs, and skepticism towards the healthcare system can diminish participation in innovative or comprehensive treatment plans²⁷.

Future Perspectives

Moving forward, addressing chemoresistance in cervical cancer will rely more on the incorporation of precision medicine, improved drug delivery systems, and a greater comprehension of tumor biology. The swift advancement of genomic and proteomic technologies provides an unparalleled chance to analyze the molecular complexities of resistance at the single-cell level. These tools will allow for the discovery of new biomarkers, therapeutic targets, and resistance signatures, ultimately aiding in the creation of personalized treatment plans customized to the distinct molecular profile of every patient's tumor²⁸.

A promising path forward lies in the ongoing development of multi-omics strategies, integrating genomic, transcriptomic, epigenomic, and metabolomic information to create a detailed map of chemoresistance mechanisms. Machine learning and artificial intelligence (AI) are increasingly crucial in interpreting this intricate data, uncovering actionable patterns, and forecasting patient reactions to treatments. These technologies have the potential to transform treatment planning by facilitating real-time tracking of resistance development and allowing early intervention prior to complete treatment failure²⁹.

In the field of pharmacology, the future is in intelligent and flexible drug delivery systems that can react to the changing tumor environment. Stimuli-responsive nanoparticles can be designed to deliver their drug load in reaction to pH, temperature, or enzymatic alterations

characteristic of tumor tissues. These advancements not only improve treatment accuracy but also minimize unintended toxicity. Moreover, studies on tumor-penetrating peptides and ligand-directed targeting seek to enhance drug accumulation in difficult-to-access or resistant tumor areas, including hypoxic regions or areas abundant in cancer stem cells³⁰. The treatment arsenal is also anticipated to grow with immunotherapy combinations and next-generation immune modulators. In addition to checkpoint inhibitors, current research into tailored cancer vaccines, adoptive T-cell therapies, and tumor microenvironment modulators may aid in re-sensitizing resistant tumors to immune and chemotherapy treatments. These approaches may change cervical cancer from being primarily resistant to chemotherapy into a condition that can be targeted and effectively managed through immunological methods over the long term^{31,32}. Crucially, implementing these innovations in clinical settings will necessitate strong clinical trial designs that incorporate biomarker-based stratification, real-world evidence, and fair global representation. The majority of clinical trials so far have taken place in high-resource environments, possibly failing to represent the patient groups most impacted by cervical cancer. Making sure that new treatments are available, affordable, and suitable for low- and middle-income nations should be an equally important focus^{33,34}.

CONCLUSIONS

Chemoresistance continues to be one of the major challenges in successfully treating cervical cancer, especially in instances of advanced or recurring illness. The complex characteristics of resistance encompassing genetic changes, modified drug metabolism, improved DNA repair processes, evasion of apoptosis, and dynamics of the tumor microenvironment highlight the significant difficulties encountered by clinicians and researchers. Even with the prevalent application of cisplatin-based chemotherapy and the inclusion of radiotherapy and targeted therapies, treatment results frequently fall short due to the tumor's capacity to adapt and endure. In recent times, considerable progress has been achieved in understanding the molecular bases of chemoresistance and in creating pharmacological approaches to mitigate them. Combination treatments, targeted molecular inhibitors, immunotherapy strategies, and nanotechnology-driven delivery systems present fresh promise for enhancing drug effectiveness and reinstating sensitivity in resistant tumors. Moreover, the emergence of precision oncology, driven by genomics and data-informed medicine, offers significant potential for customizing treatment for unique patient profiles and proactively tackling resistance mechanisms.

ACKNOWLEDGEMENTS

The author would like to thank Africa University, Zimbabwe to provide necessary facilities for this work.

AUTHOR'S CONTRIBUTION

Ezeala CC: conceived the idea, writing the manuscript, literature survey, formal analysis, critical review. Final manuscript was checked and approved by the both authors.

DATA AVAILABILITY

Data will be made available on request.

CONFLICT OF INTEREST

There are no conflicts of interest in regard to this project.

REFERENCES

1. Reza S, Anjum R, Khandoker RZ, *et al.* Public health concern-driven insights and response of low-and middle-income nations to the World health Organization call for cervical cancer risk eradication. *Gynecologic Oncol Repo* 2024; 54:101460. <https://doi.org/10.1016/j.gore.2024.101460>
2. Wang M, Huang K, Wong MC, *et al.* Global cervical cancer incidence by histological subtype and implications for screening methods. *J Epide Glo Health* 2024;14(1):94-101.
3. Obeagu EI. From inflammation to invasion: Neutrophils in cervical cancer pathogenesis. *Ann Med Surg* 2024;10:97. <https://doi.org/10.1097/MS9.0000000000002679>
4. Obeagu EI, Obeagu GU. Beyond traditional screening: Unleashing the potential of cancer antigen 27.29 for early breast cancer identification. *Elit J Health Sci* 2024;2(2):36-45.
5. Obeagu EI, Mahmoud SA. Monocytes and cervical ripening: A narrative review of prolonged labor pathophysiology. *Ann Med Surg* 2025;10:97. <https://doi.org/10.1097/MS9.0000000000003004>
6. Akandinda M, Obeagu EI, Madekwe CC, *et al.* A review on factors associated with hpv vaccination in Africa. *Mad Uni J Med Health Sci* 2022;2(3):1-5.
7. Ronsini C, Solazzo MC, Braca E, *et al.* Locally advanced cervical cancer: Neoadjuvant treatment versus standard radio-chemotherapy-An updated meta-analysis. *Canc* 2024 ;16(14):2542. <https://doi.org/10.3390/cancers16142542>
8. Yeshe P, Li F. Clinical efficacy and safety of neoadjuvant chemotherapy with paclitaxel and cisplatin in combination with concurrent chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis. *J Radi Res* 2024;65(6):733-743. <https://doi.org/10.1093/jrr/rrae073>
9. Mbodi L, Maringa VD, Moroeng MW *et al.* An overview of cervical cancer, chemotherapy as treatment and chemotherapy resistance. *Strat Over Chemo Resis Cervi Canc* 2024;1-6. <https://doi.org/10.1016/B978-0-443-28985-9.00017-3>
10. Mukherjee A, Manna S, Singh A, *et al.* Investigating cisplatin resistance in squamous cervical cancer: Proteomic insights into dna repair pathways and omics-based drug repurposing. *J Prot Res* 2025. <https://doi.org/10.1021/acs.jproteome.4c00885>
11. Marima R, Mosoane B, Mtshali N, *et al.* Mechanisms of chemotherapy resistance in cervical cancer. *Strat Over Chemo Resis Cervi Canc* 2024; 53-70. Academic Press.
12. Liu Z, Liu J, Wu Y, *et al.* Shared chemoresistance genes in ESCC and cervical Cancer: Insig pharmaco and Mend random. *Inter Immun Pharm* 2025; 147:113933. <https://doi.org/10.1016/j.intimp.2024.113933>
13. Chen X, Yang N, Wang Y, *et al.* PKC1-mediated glycogenolysis facilitates ROS clearance and chemotherapy resistance in cervical cancer stem cells. *Sci Repor* 2024;14(1):13670. <https://doi.org/10.1038/s41598-024-64255-6>
14. De Sousa C, Eksteen C, Riedemann J, *et al.* Highlighting the role of CD44 in cervical cancer progression: Immunotherapy's potential in inhibiting metastasis and chemoresistance. *Immuno Res* 2024;72(4):592-604. <https://doi.org/10.1007/s12026-024-09493-6>
15. Gu Y, Yang R, Zhang Y, *et al.* Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. *Mol Bio Med* 2025;6(1):2. <https://doi.org/10.1186/s43556-024-00239-2>
16. Shruthi S, Bhasker Shenoy K. Cisplatin resistance in cancer therapy: Causes and overcoming strategies. *Chem Sel* 2024;9(25): e202401449. <https://doi.org/10.1002/slct.202401449>
17. D'Oria O, Bogani G, Cuccu I, *et al.* Pharmacotherapy for the treatment of recurrent cervical cancer: An update of the literature. *Exp Opin Pharmaco* 2024;25(1):55-65. <https://doi.org/10.1080/14656566.2023.2298329>
18. Carobeli LR, Santos AB, Martins LB, *et al.* Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: A systematic review. *Exp Rev Anticancer Thera* 2024;24(5):263-282. <https://doi.org/10.1080/14737140.2024.2337259>
19. Srinivasan G. Cervical cancer: Novel treatment strategies offer renewed optimism. *Path-Res Pract* 2024; 254:155136. <https://doi.org/10.1016/j.prp.2024.155136>
20. Sun W, Cai H, Zhang K, *et al.* Targeting MCL1 with sanggenon C overcomes MCL1-driven adaptive chemoresistance via dysregulation of autophagy and endoplasmic reticulum stress in cervical cancer. *Phytomed* 2024; 133:155935. <https://doi.org/10.1016/j.phymed.2024.155935>
21. Rasizadeh R, Aghbash PS, Mokhtarzadeh A, Poortahmasebi V, Oskouee MA, Nahand JS, Amini M, Mahdavi SZ, Yari AH, Baghi HB. Novel strategies in HPV-16-related cervical cancer treatment: An *in vitro* study of combined siRNA-E5 with oxaliplatin and ifosfamide chemotherapy. *Gene* 2025; 932:148904.
22. Khan SU, Fatima K, Aisha S, *et al.* Unveiling the mechanisms and challenges of cancer drug resistance. *Cell Comm Signa* 2024;22(1):109. <https://doi.org/10.1186/s12964-023-01302-1>
23. Deng S, Yuan P, Sun J. The role of NF-κB in carcinogenesis of cervical cancer: Opportunities and challenges. *Mol Bio Repo* 2024;51(1):538. <https://doi.org/10.1007/s11033-024-09447-z>
24. Mubthasima PP, Singh SA, Kannan A. Sesamol-mediated targeting of EPHA2 sensitises cervical cancer for cisplatin treatment by regulating mitochondrial dynamics, autophagy, and mitophagy. *Mol Bio Repo* 2024;51(1):949. <https://doi.org/10.1007/s11033-024-09875-x>
25. Liu Z, Liu J, Wu Y, *et al.* Shared chemoresistance genes in ESCC and cervical Cancer: Insights from pharmacogenomics and Mendelian randomization. *Inter Immun Pharma* 2025; 147:113933. <https://doi.org/10.1016/j.intimp.2024.113933>
26. Maitra S, Mukerjee N, Alharbi HM, *et al.* Targeted therapies for HPV-associated cervical cancer: Harnessing the potential of exosome-based chipsets in combating leukemia and HPV-mediated cervical cancer. *J Med Viro* 2024;96(4): e29596. <https://doi.org/10.1002/jmv.29596>
27. Demetriou D, Mbatha SZ, McCabe M, *et al.* MicroRNA involvement in cervical cancer chemotherapy drug resistance: Restoring sensitivity to chemotherapeutic drugs. In *Strategies for overcoming chemotherapy resistance in cervical cancer* 2024: 139-154. Academic Press. <https://doi.org/10.1016/B978-0-443-28985-9.00014-8>
28. Garg P, Krishna M, Subbalakshmi AR, *et al.* Emerging biomarkers and molecular targets for precision medicine in cervical cancer. *Biochi Biophy Acta (BBA)- Rev Cancer* 2024;189106.<https://doi.org/10.1016/j.bbcan.2024.189106>

29. Damane BP, Mulaudzi TV, Kgokolo MC, *et al.* Future directions in cervical cancer treatment. In Strategies for overcoming chemotherapy resistance in cervical cancer 2024: 155-177. Academic Press.
<https://doi.org/10.1016/B978-0-443-28985-9.00004-5>
30. Xu M, Cao C, Wu P, *et al.* Advances in cervical cancer: Current insights and future directions. Can Commu 2025;45(2):77-109. <https://doi.org/10.1002/cac2.12629>
31. Aswathy R, Sumathi S. The evolving landscape of cervical cancer: breakthroughs in screening and therapy through integrating biotechnology and artificial intelligence. Mole Biotech 2025;67(3):925-941.
<https://doi.org/10.1007/s12033-024-01124-7>
32. Hakim RU, Amin T, Ul Islam SB. Advances and challenges in cervical cancer: From molecular mechanisms and global epidemiology to innovative therapies and prevention strategies. Cancer Cont 2025; 32:10732748251336415.
<https://doi.org/10.1177/10732748251336415>
33. Devi S, Giri J, Makki E, *et al.* Navigating the novel nanoparticles: Current insights, innovations, and future vistas in detection and treatment of cervical cancer. Nano comp 2024;10(1):256-282.
<https://doi.org/10.1080/20550324.2024.2362504>
34. Dey T, Agrawal S. Immunotherapy in cervical cancer: An innovative approach for better treatment outcomes. Explor Targ Anti-tumor Thera 2025; 6:1002296.
<https://doi.org/10.37349/etat.2025.1002296>